Scarica l'app Stockscreener
35.78
2.40%
-0.88
Dopo l'orario di chiusura:
35.78
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BHVN Giù?
Forum
Previsione
Precedente Chiudi:
$36.66
Aprire:
$36.18
Volume 24 ore:
773.97K
Relative Volume:
0.82
Capitalizzazione di mercato:
$3.62B
Reddito:
-
Utile/perdita netta:
$-804.34M
Rapporto P/E:
-4.7898
EPS:
-7.47
Flusso di cassa netto:
$-531.06M
1 W Prestazione:
-1.02%
1M Prestazione:
-22.23%
6M Prestazione:
+3.08%
1 anno Prestazione:
-16.40%
Intervallo 1D:
$35.25
$36.66
Intervallo di 1 settimana:
$34.53
$37.27
Portata 52W:
$26.80
$62.21
Biohaven Ltd Stock (BHVN) Company Profile
Nome
Biohaven Ltd
Settore
Industria
Telefono
203-404-0410
Indirizzo
215 CHURCH STREET, NEW HAVEN, CT
Confronta BHVN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
35.78 | 3.62B | 0 | -804.34M | -531.06M | -9.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
399.35 | 102.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
702.59 | 77.21B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
619.96 | 37.07B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.01 | 30.44B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
112.58 | 26.99B | 3.30B | -501.07M | 1.03B | -2.1146 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-16 | Iniziato | Jefferies | Buy |
| 2024-09-04 | Iniziato | Bernstein | Outperform |
| 2024-07-24 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-02-06 | Iniziato | UBS | Buy |
| 2023-12-22 | Iniziato | H.C. Wainwright | Buy |
| 2023-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-01-24 | Iniziato | SVB Securities | Outperform |
| 2023-01-04 | Iniziato | JP Morgan | Overweight |
| 2022-12-02 | Iniziato | BTIG Research | Buy |
| 2022-10-26 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | Iniziato | Piper Sandler | Overweight |
| 2022-08-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-05-11 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-08-10 | Downgrade | UBS | Buy → Neutral |
| 2021-08-03 | Reiterato | Canaccord Genuity | Buy |
| 2021-03-11 | Iniziato | UBS | Buy |
| 2020-12-15 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-17 | Iniziato | Cowen | Outperform |
| 2020-02-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2019-11-22 | Iniziato | Wedbush | Outperform |
| 2019-06-25 | Reiterato | Canaccord Genuity | Buy |
| 2019-05-06 | Iniziato | Goldman | Buy |
| 2019-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | Reiterato | Needham | Buy |
| 2018-07-03 | Reiterato | Needham | Buy |
| 2018-07-02 | Reiterato | Needham | Buy |
| 2018-04-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2018-02-22 | Reiterato | Canaccord Genuity | Buy |
| 2017-12-15 | Iniziato | Canaccord Genuity | Buy |
| 2017-10-03 | Reiterato | Needham | Buy |
Mostra tutto
Biohaven Ltd Borsa (BHVN) Ultime notizie
Biohaven Ltd. (NYSE:BHVN) Receives $63.00 Average Price Target from Brokerages - MarketBeat
Biohaven Enters Oversold Territory (BHVN) - Nasdaq
How To Trade (BHVN) - Stock Traders Daily
Geode Capital Management LLC Purchases 44,174 Shares of Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Bernstein reiterates Outperform rating on Biohaven stock, sees strong upside potential By Investing.com - Investing.com South Africa
Biohaven (NYSE:BHVN) Stock Price Down 6.1%What's Next? - MarketBeat
Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval - AOL
Bernstein reiterates Outperform rating on Biohaven stock, sees strong upside potential - Investing.com Australia
Biohaven's (BHVN) Overweight Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Biohaven (NYSE:BHVN) Given Buy Rating at HC Wainwright - MarketBeat
Is Biohaven Ltd. (BHVN) the Best Weight Loss Stock to Buy Now According to Hedge Funds? - Insider Monkey
Biohaven (NYSE:BHVN) Shares Gap DownWhat's Next? - MarketBeat
Biohaven Pharma (BHVN) Reports Positive Phase 1 Degrader Data - StreetInsider.com
Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates - PR Newswire
Biohaven Ltd. (NYSE:BHVN) Holdings Boosted by Barclays PLC - MarketBeat
Wellington Management Group LLP Boosts Stock Holdings in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven's SWOT analysis: neurological drug developer's stock poised for growth - Investing.com
12 Best Weight Loss Stocks to Buy According to Hedge Funds - Insider Monkey
State Street Corp Sells 393,278 Shares of Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven Announces Proposed Public Offering of Common Shares - The Eastern Progress Online
Learn to Evaluate (BHVN) using the Charts - Stock Traders Daily
Y Intercept Hong Kong Ltd Acquires Shares of 26,789 Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven Announces Pricing of $250 Million Public Offering of Common Shares - The Eastern Progress Online
Biohaven Ltd. (NYSE:BHVN) Shares Acquired by XTX Topco Ltd - MarketBeat
Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine - The Eastern Progress Online
Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Rel - GuruFocus.com
Biohaven Pharma (BHVN) Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates - StreetInsider.com
Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting – Company AnnouncementFT.com - Financial Times
Fmr LLC Sells 13,092 Shares of Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Stifel Financial Corp Purchases 28,684 Shares of Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven Ltd. (NYSE:BHVN) Shares Sold by Redmile Group LLC - MarketBeat
Point72 Asset Management L.P. Has $74.97 Million Stock Position in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven Ltd. (NYSE:BHVN) Stock Position Raised by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Biohaven shares target increased, rating held on FDA catalyst potential By Investing.com - Investing.com Australia
Charles Schwab Investment Management Inc. Has $31.62 Million Stock Position in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Janus Henderson Group PLC Boosts Stock Position in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Holocene Advisors LP Lowers Stock Position in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Erste Asset Management GmbH Invests $2.62 Million in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Analysts Set Biohaven Ltd. (NYSE:BHVN) Price Target at $62.75 - MarketBeat
Trading (BHVN) With Integrated Risk Controls - Stock Traders Daily
Fred Alger Management LLC Grows Position in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
D.A. Davidson & CO. Makes New $1.20 Million Investment in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Intech Investment Management LLC Acquires New Stake in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Citigroup Inc. Has $5.99 Million Position in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven Ltd. (NYSE:BHVN) Shares Sold by Eventide Asset Management LLC - MarketBeat
Biohaven's Revenue Path: SCA And Obesity Therapies (NYSE:BHVN) - Seeking Alpha
Algert Global LLC Acquires 24,990 Shares of Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven’s Phase III SMA miss: was it the target or the trial design? - BioCentury
Biohaven's (BHVN) Buy Rating Reiterated at HC Wainwright - MarketBeat
Scholar Rock shares surge 26% as rival Biohaven misses SMA study goal - TradingPedia
Biohaven’s myostatin inhibitor fails in phase 3 spinal muscular atrophy trial - BioPharma-Reporter.com
Biohaven Ltd Azioni (BHVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Biohaven Ltd Azioni (BHVN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Coric Vlad | Chief Executive Officer |
Oct 02 '24 |
Buy |
47.50 |
21,052 |
999,970 |
861,942 |
| Bailey Gregory | Director |
Sep 24 '24 |
Buy |
44.19 |
5,000 |
220,966 |
1,620,071 |
| CHILDS JOHN W | Director |
Jul 18 '24 |
Buy |
35.67 |
28,400 |
1,012,983 |
2,339,741 |
| Car Bruce | Chief Scientific Officer |
Jun 17 '24 |
Buy |
33.58 |
30,000 |
1,007,490 |
30,000 |
| CHILDS JOHN W | Director |
May 30 '24 |
Buy |
35.58 |
28,000 |
996,240 |
2,311,341 |
| Bailey Gregory | Director |
May 13 '24 |
Buy |
34.19 |
15,000 |
512,877 |
1,615,071 |
| CHILDS JOHN W | Director |
May 13 '24 |
Buy |
35.17 |
28,500 |
1,002,470 |
2,283,341 |
| Bailey Gregory | Director |
Apr 24 '24 |
Buy |
39.18 |
25,503 |
999,169 |
1,600,071 |
| Bailey Gregory | Director |
Apr 22 '24 |
Buy |
41.00 |
48,780 |
1,999,980 |
1,574,568 |
| CHILDS JOHN W | Director |
Apr 22 '24 |
Buy |
41.00 |
195,121 |
7,999,961 |
4,096,512 |
1.76%
1.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):